At a glance
- Originator Sanofi-Synthelabo
- Class Antihypertensives
- Mechanism of Action Renin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Glaucoma
- Discontinued Hypertension
Most Recent Events
- 30 Aug 1999 Sanofi has merged with Synthélabo to form Sanofi-Synthélabo
- 22 Aug 1997 Preclinical development for Glaucoma (Ophthalmic)
- 01 Jun 1995 Discontinued-II for Hypertension in France (IV-infusion)